Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease

  • Morenas-Rodríguez, Estrella|||0000-0002-7591-6051
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Muñoz, Laia|||0000-0003-0578-3094
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Subirana, Andrea
  • Querol-Vilaseca, Marta|||0000-0002-8589-1636
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Ribosa-Nogué, Roser|||0000-0002-9233-4336
  • Blesa, Rafael|||0000-0003-4026-2884
  • Haass, Christian|||0000-0002-4869-1627
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
The role of innate immunity in dementia with Lewy bodies (DLB) has been little studied. We investigated the levels in cerebrospinal fluid (CSF) of glial proteins YKL-40, soluble TREM2 (sTREM2) and progranulin in DLB and their relationship with Alzheimer's disease (AD) biomarkers. We included patients with DLB (n = 37), prodromal DLB (prodDLB, n = 23), AD dementia (n = 50), prodromal AD (prodAD, n = 53), and cognitively normal subjects (CN, n = 44). We measured levels of YKL-40, sTREM2, progranulin, Aβ, total tau (t-tau) and phosphorylated tau (p-tau) in CSF. We stratified the group DLB according to the ratio t-tau/Aβ (≥0.52, indicative of AD pathology) and the A/T classification. YKL-40, sTREM2 and progranulin levels did not differ between DLB groups and CN. YKL-40 levels were higher in AD and prodAD compared to CN and to DLB and prodDLB. Patients with DLB with a CSF profile suggestive of AD copathology had higher levels of YKL-40, but not sTREM2 or PGRN, than those without. T+ DLB patients had also higher YKL-40 levels than T-. Of these glial markers, only YKL-40 correlated with t-tau and p-tau in DLB and in prodDLB. In contrast, in prodAD, sTREM2 and PGRN also correlated with t-tau and p-tau. In conclusion, sTREM2 and PGRN are not increased in the CSF of DLB patients. YKL-40 is only increased in DLB patients with an AD biomarker profile, suggesting that the increase is driven by AD-related neurodegeneration. These data suggest a differential glial activation between DLB and AD.